Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
Eosinophilic Esophagitis is a food driven non-IgE mediated disease involving eosinophils and
type 2 inflammation. Current therapies include diet and the off label use of medications
including proton pump inhibitors, topical steroids or biologics. Food elimination creates a
decrease quality of life in many children. The goal of the study is to examine a T2 inhibitor
(dupilumab) can allow successful reintroduction of allergic EoE foods into the diet.
Phase:
Phase 4
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborators:
Genzyme, a Sanofi Company Regeneron Pharmaceuticals